Top entities: Ipsen, Memo Therapeutics, Euronext Paris, France — Autorité des marchés financiers.

What category does this event fall under?

Business — classified as acquisition.

What is the sentiment of coverage?

Aggregate sentiment score: 40 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Ipsen acquired Memo Therapeutics · Ipsen acquired Kartos Therapeutics · Memo Therapeutics presented phase 2 data

Is this event still developing?

This is an active story, last updated Jul 22, 2026. Coverage continues to evolve.

Business acquisition

Ipsen acquires Memo Therapeutics

Q: When did this event occur?

First reported Jul 01, 2026; last updated Jul 22, 2026.

Q: What is the market impact?

General. The acquisition expands Ipsen's rare disease pipeline with a first-in-class asset addressing an unmet medical need in kidney transplantation.

Analysis based on 17 articles · First reported Jul 01, 2026 · Last updated Jul 22, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The acquisition expands Ipsen's rare disease pipeline with a first-in-class asset addressing an unmet medical need in kidney transplantation. This could enhance Ipsen's growth prospects and competitive position in the rare disease market.

Biotechnology Pharmaceuticals

Event Summary

Ipsen (Euronext Paris: IPN; ADR: IPSEY) announced on 22 July 2026 that it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. Potravitug is a first-in-class monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. It has shown promising results in the Phase II SAFE KIDNEY II trial, demonstrating significant anti-viral response and resolution of BKPyV associated nephropathy. BK polyomavirus is a common virus that can reactivate in immunocompromised individuals, including kidney transplant recipients, and can lead to graft loss. There are currently no approved targeted therapies for BKPyV. The acquisition strengthens Ipsen's Rare Disease pipeline. Financial terms were not disclosed.

Key Actions

100 Ipsen acquired Memo Therapeutics

80 Ipsen acquired Kartos Therapeutics

50 Memo Therapeutics presented phase 2 data

30 Ipsen granted fast-track designation United States — Food and Drug Administration

20 European Union granted orphan drug designation Memo Therapeutics

10 Memo Therapeutics transferred non-potravitug assets Memo Therapeutics

Entities Involved

stock

Ipsen

Ipsen completed the acquisition of Memo Therapeutics, adding potravitug to its rare disease pipeline, which may drive future revenue growth.

Importance 100.0 Sentiment 50.0

priv

Memo Therapeutics

Memo Therapeutics was acquired by Ipsen, providing an exit for its investors and advancing its lead asset, potravitug, under a larger pharmaceutical company.

Importance 80.0 Sentiment 60.0

exch

Euronext Paris

Euronext Paris is the stock exchange where Ipsen is listed; the acquisition may influence Ipsen's stock price but has no direct impact on Euronext Paris.

Importance 10.0 Sentiment 0.0

govactor

France — Autorité des marchés financiers

The AMF is the French financial regulator; Ipsen's acquisition is subject to its regulations, but no specific regulatory action is reported.

Importance 5.0 Sentiment 0.0

Relationships

Euronext Paris related ↔ France — Autorité des marchés financiers

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard